Northwest Biotherapeutics Inc (NWBO) stock
NWBOOTCPharmaceutical PreparationsFiscal year ends December 31
$0.16−0.00 (-0.88%)
Close on Oct 19, 2026Market cap $254.79MP/E –Yield –
Northwest Biotherapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Northwest Biotherapeutics's operating margin for the twelve months ending Jun 30, 2026 was -2316.1%. For fiscal 2025 it was -4347.9%, against -4812.4% the year before. The highest annual figure on record is -1161.0% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -4347.9% | +464.6 |
| FY2024 | Dec 31, 2024 | -4812.4% | −1939.4 |
| FY2023 | Dec 31, 2023 | -2873.1% | +1118.7 |
| FY2022 | Dec 31, 2022 | -3991.7% | +1252.2 |
| FY2021 | Dec 31, 2021 | -5244.0% | +1464.4 |
| FY2020 | Dec 31, 2020 | -6708.4% | −5547.4 |
| FY2019 | Dec 31, 2019 | -1161.0% | +8907.2 |
| FY2018 | Dec 31, 2018 | -10068.2% | +6205.0 |
| FY2017 | Dec 31, 2017 | -16273.2% | −3549.9 |
| FY2016 | Dec 31, 2016 | -12723.3% | −5461.4 |
| FY2015 | Dec 31, 2015 | -7261.9% | −305.7 |
| FY2014 | Dec 31, 2014 | -6956.2% | −99.1 |
| FY2013 | Dec 31, 2013 | -6857.1% | −1180.3 |
| FY2012 | Dec 31, 2012 | -5676.8% | +262193.2 |
| FY2011 | Dec 31, 2011 | -267870.0% | −114330.0 |
| FY2010 | Dec 31, 2010 | -153540.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1438.0% | +9843.6 |
| Q1 FY2026 | Mar 31, 2026 | -2206.5% | +2409.8 |
| Q4 FY2025 | Dec 31, 2025 | -2009.5% | +5998.7 |
| Q3 FY2025 | Sep 30, 2025 | -7160.0% | −3014.1 |
| Q2 FY2025 | Jun 30, 2025 | -11281.7% | −7857.4 |
| Q1 FY2025 | Mar 31, 2025 | -4616.3% | +927.4 |
| Q4 FY2024 | Dec 31, 2024 | -8008.2% | −4605.5 |
| Q3 FY2024 | Sep 30, 2024 | -4145.9% | −740.8 |
| Q2 FY2024 | Jun 30, 2024 | -3424.3% | +3330.4 |
| Q1 FY2024 | Mar 31, 2024 | -5543.7% | −4070.5 |
| Q4 FY2023 | Dec 31, 2023 | -3402.7% | −357.8 |
| Q3 FY2023 | Sep 30, 2023 | -3405.2% | +4176.4 |
| Q2 FY2023 | Jun 30, 2023 | -6754.7% | −2331.5 |
| Q1 FY2023 | Mar 31, 2023 | -1473.2% | +1575.5 |
| Q4 FY2022 | Dec 31, 2022 | -3044.9% | −173.7 |
| Q3 FY2022 | Sep 30, 2022 | -7581.6% | −2937.6 |
| Q2 FY2022 | Jun 30, 2022 | -4423.3% | +17742.0 |
| Q1 FY2022 | Mar 31, 2022 | -3048.6% | +373751.4 |
| Q3 FY2021 | Sep 30, 2021 | -2871.1% | −1496.9 |
| Q4 FY2020 | Dec 31, 2020 | -4643.9% | −3893.4 |
| Q3 FY2020 | Sep 30, 2020 | -22165.3% | −21054.8 |
| Q2 FY2020 | Jun 30, 2020 | -376800.0% | −375657.7 |
| Q1 FY2020 | Mar 31, 2020 | -1374.2% | +916.6 |
| Q4 FY2019 | Dec 31, 2019 | -750.5% | +1306.7 |
| Q3 FY2019 | Sep 30, 2019 | -1110.5% | +6211.1 |
| Q2 FY2019 | Jun 30, 2019 | -1142.3% | +5536.4 |
| Q1 FY2019 | Mar 31, 2019 | -2290.9% | +53884.1 |
| Q3 FY2018 | Sep 30, 2018 | -2057.2% | +27869.6 |
| Q2 FY2018 | Jun 30, 2018 | -7321.6% | +8726.2 |
| Q1 FY2018 | Mar 31, 2018 | -6678.8% | +2890.0 |
| Q4 FY2017 | Dec 31, 2017 | -56175.0% | −48768.6 |
| Q4 FY2016 | Dec 31, 2016 | -29926.8% | −23972.4 |
| Q3 FY2016 | Sep 30, 2016 | -16047.8% | – |
| Q2 FY2016 | Jun 30, 2016 | -9568.8% | – |
| Q1 FY2016 | Mar 31, 2016 | -7406.4% | – |
| Q4 FY2015 | Dec 31, 2015 | -5954.3% | – |
See a number that looks wrong?